ASP Isotopes Inc. (ASPI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ASP Isotopes Inc. (ASPI) Materials & Commodity Exposure

ASP Isotopes Inc. is a pre-commercial stage advanced materials company specializing in isotope production for medical and energy sectors. With a focus on Molybdenum-100, Carbon-14, Silicon-28, and Uranium-235, the company aims to serve the growing demand for isotopes in specialized applications, differentiating itself through advanced material development.

What Is the Investment Thesis for ASPI?

ASP Isotopes Inc. presents a speculative investment opportunity in the advanced materials sector, specifically in the niche market of isotope production. The company's focus on isotopes like Molybdenum-100 for medical applications and Uranium-235 for carbon-free energy positions it in potentially high-growth areas. However, as a pre-commercial stage company with a negative profit margin of -734.2% and a gross margin of 14.3%, the investment carries significant risk. The high beta of 3.57 indicates high volatility relative to the market. Successful development and commercialization of its isotope production capabilities are critical for future revenue generation and profitability. Investors should closely monitor the company's progress in securing contracts and scaling production.

Based on FMP financials and quantitative analysis

ASPI Key Highlights

Market capitalization of $452M reflects investor expectations despite the pre-commercial stage.

• Gross margin of 14.3% indicates potential for profitability upon scaling production.
• Profit margin of -734.2% highlights the current lack of revenue and high operational costs associated with the development phase.
• Beta of 3.57 suggests high volatility compared to the broader market, typical for early-stage companies.
• Focus on Molybdenum-100 and Uranium-235 positions the company in growing markets within the medical and energy sectors.

Who Are ASPI's Competitors?

ASPI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ASPI's Key Strengths?

Focus on high-demand isotopes.

• Potential for growth in medical and energy sectors.
• Proprietary production processes.
• Experienced management team.

What Are ASPI's Weaknesses?

Pre-commercial stage with no significant revenue.

• Negative profit margin.
• High operational costs.
• Dependence on successful development and commercialization.

What Could Drive ASPI Stock Higher?

Securing contracts with medical device manufacturers for Molybdenum-100 supply.

• Achieving milestones in the development of Carbon-14 production capabilities.
• Establishing partnerships with semiconductor manufacturers for Silicon-28 supply.
• Advancing the commercialization of Uranium-235 for carbon-free energy applications.

What Are the Key Risks for ASPI?

Financial-distress signal — its Altman Z-Score of 0.00 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Delays in the development and commercialization of isotope production capabilities.
• Competition from established isotope producers.
• Regulatory hurdles and compliance requirements.
• Dependence on securing funding for research and development activities.
• Market acceptance of ASP Isotopes' products and technologies.

What Are the Growth Opportunities for ASPI?

• Growth opportunity 1: Expanding Molybdenum-100 Production for Medical Applications: The market for Molybdenum-100 in medical imaging and cancer treatment is growing, driven by advancements in diagnostic techniques and targeted therapies. ASP Isotopes can capitalize on this by scaling up its production capacity and securing contracts with medical device manufacturers and healthcare providers.
• Growth opportunity 2: Developing Carbon-14 for Research and Environmental Monitoring: Carbon-14 is used in various research applications, including carbon dating and environmental monitoring. ASP Isotopes can expand its market share by developing high-purity Carbon-14 and establishing partnerships with research institutions and environmental agencies. The market for Carbon-14 is driven by increasing research activities and growing concerns about climate change.
• Growth opportunity 3: Supplying Silicon-28 for Advanced Semiconductor Manufacturing: Silicon-28 is used in the production of advanced semiconductors, offering improved thermal conductivity and performance. ASP Isotopes can target semiconductor manufacturers by providing high-quality Silicon-28 and collaborating on research and development projects. The semiconductor industry is experiencing rapid growth, driven by increasing demand for electronics and computing devices.
• Growth opportunity 4: Commercializing Uranium-235 for Carbon-Free Energy: Uranium-235 is a key component in nuclear reactors, providing a carbon-free energy source. ASP Isotopes can capitalize on the growing demand for nuclear energy by securing contracts with nuclear power plants and developing advanced fuel technologies. The global nuclear energy market is expected to grow significantly as countries seek to reduce carbon emissions.
• Growth opportunity 5: Establishing Strategic Partnerships and Collaborations: ASP Isotopes can accelerate its growth by forming strategic partnerships with established companies in the medical, research, semiconductor, and energy sectors. These partnerships can provide access to new markets, technologies, and funding opportunities. Collaborations with research institutions can also enhance the company's research and development capabilities.

What Are ASPI's Competitive Advantages?

• Specialized isotope production capabilities.
• Focus on isotopes for high-growth markets.
• Proprietary production processes for specific isotopes.
• Relationships with key players in the medical, research, semiconductor, and energy sectors.

What Does ASPI Do?

ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida. It operates as a pre-commercial stage advanced materials company focused on the production, distribution, marketing, and sale of isotopes. The company's primary focus is on developing and supplying various isotopes, including Molybdenum-100, Carbon-14, Silicon-28, and Uranium-235. Molybdenum-100 is a non-radioactive isotope used in the medical industry for diagnostic imaging and cancer treatment. Carbon-14 is utilized in research and environmental monitoring. Silicon-28 finds applications in advanced semiconductor manufacturing. Uranium-235 is an isotope of uranium used in the carbon-free energy industry, specifically in nuclear reactors. ASP Isotopes aims to capitalize on the increasing demand for isotopes in these specialized applications. The company is currently in the pre-commercial stage, focusing on research, development, and establishing production capabilities to serve these markets.

What Products and Services Does ASPI Offer?

• Produces Molybdenum-100 for medical imaging and cancer treatment.
• Develops Carbon-14 for research and environmental monitoring.
• Produces Silicon-28 for advanced semiconductor manufacturing.
• Produces Uranium-235 for carbon-free energy generation.
• Focuses on the production, distribution, and marketing of isotopes.
• Aims to supply isotopes to various industries, including medical, research, and energy.

How Does ASPI Make Money?

• ASP Isotopes generates revenue through the sale of isotopes.
• The company focuses on producing and distributing isotopes to various industries.
• The business model involves developing and commercializing isotopes for specialized applications.

What Industry Does ASPI Operate In?

ASP Isotopes Inc. operates within the chemicals industry, specifically focusing on the niche market of isotope production. The demand for isotopes is driven by applications in medical diagnostics, cancer treatment, research, semiconductor manufacturing, and nuclear energy. The market is characterized by specialized production processes and stringent regulatory requirements. Competitors include established chemical companies and specialized isotope producers. ASP Isotopes aims to differentiate itself through its focus on specific isotopes and its advanced material development capabilities. The growth of the medical and energy sectors is expected to drive demand for isotopes, presenting opportunities for companies like ASP Isotopes.

Who Are ASPI's Key Customers?

• Medical device manufacturers using Molybdenum-100.
• Research institutions utilizing Carbon-14.
• Semiconductor manufacturers using Silicon-28.
• Nuclear power plants using Uranium-235.

ASP Isotopes Inc. (ASPI) Valuation Context

Valued at $452M, ASPI is classified as a small-cap stock. Analyst price targets span from $4.50 to $15.00, with a consensus of $9.50. At the current price of $3.59, that implies approximately 165% upside potential.

ASPI Revenue & Earnings Trend

In Jun 2026, ASPI generated $5.1M in top-line revenue, marking a sequential increase of 22.6%. The company recorded a net loss of $33.6M, with diluted EPS of $-0.27. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Basic Materials. Across the four most recent quarters, ASPI averaged $-0.33 in diluted EPS.

Company Profile

ASP Isotopes Inc. operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in Dallas, US. The company is led by CEO Paul Elliot Mann. ASPI has traded publicly since 2022.

Key Financial Metrics

Return on assets is -29.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.4%, the inverse of the P/E and a quick read on earnings relative to price.

ASP Isotopes Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.00 places it in the distress zone, a signal of elevated financial risk.

ASP Isotopes Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 110.3% below estimates on average.

Wall Street analysts project ASP Isotopes Inc. revenue of about $30.0M for fiscal 2026, with EPS near $-0.47.

Over the past six months, ASP Isotopes Inc. insiders filed 21 SEC Form 4 transactions — 17 sales and 4 purchases. On net that is roughly 3.4M shares acquired (about $5.1M) — insiders putting money in tends to read as conviction.

ASPI Financials

ASPI Latest News

ASPI Analyst Consensus

ASPI MoonshotScore

ASP Isotopes Inc. Basic Materials Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources